Meeting
2013 ASCO Annual Meeting
Tumor-related and treatment-related colostomy-free survival (CFS) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA): Results of ACT II.
Authors
Robert Glynne-Jones
Mount Vernon Centre for Cancer Treatment, Middlesex, United Kingdom
Robert Glynne-Jones , Latha Kadalayil , Helen Meadows , David Cunningham , Leslie M. Samuel , Ian Geh , Charles Lowdell , Roger David James , Sandy Beare , Rubina Begum , Jonathan A. Ledermann , David Sebag-Montefiore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00025090
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3532)
DOI
10.1200/jco.2013.31.15_suppl.3532
Abstract #
3532
Poster Bd #
24
Abstract Disclosures
Similar Posters
First Author: Robert Glynne-Jones
Poster
2011 Gastrointestinal Cancers Symposium
Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective.
First Author: Cathy Eng
First Author: Robert Glynne-Jones
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila